A Possible Marker for No-Reflow in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: Serum Endocan

Abstract

Get full access to this article

View all access options for this article.

References

Dogdus

Yenercag

Ozyasar

, et al. Serum Endocan Levels Predict Angiographic No-Reflow Phenomenon in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Intervention [published online ahead of print, 2020 Sep 30]. Angiology. 2021;72:221–7.

Ndrepepa

Tiroch

Fusaro

, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010; 55: 2383–9.

Şimşek

Çınar

Ozan

, et al. The association of acute-to-chronic glycemic ratio with no-reflow in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention [published online ahead of print, 2020 Dec 31]. Kardiol Pol. 2020;10.33963/KP.15736. doi:10.33963/KP.15736

Brosh

Assali

Mager

, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol. 2007; 99: 442–5.

Araszkiewicz

Grajek

Lesiak

, et al. Effect of impaired myocardial reperfusion on left ventricular remodeling in patients with anterior wall acute myocardial infarction treated with primary coronary intervention. Am J Cardiol. 2006;98:725–8.

Yilmaz

Siriopol

Saglam

, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86:1213–20.